Skip to main content
Fig. 2 | Experimental Hematology & Oncology

Fig. 2

From: Physical activity improves outcomes of combined lenvatinib plus anti-PD-1 therapy in unresectable hepatocellular carcinoma: a retrospective study and mouse model

Fig. 2

Voluntary running improved the effect of combination therapy in HCC mouse model. A Average running distance per mouse per week in the combination therapy plus physical activity group. B Tumor growth and C survival (time to 20 mm in maximum diameter) of subcutaneously implanted HCC mice. D Tumor viability assessed in Hematoxylin and eosin slides from the subcutaneous HCC mouse model. Representative images captured at 40 ×. * P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. HCC hepatocellular carcinoma

Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us